Researchers found that a drug developed by Novartis to lower levels of lipoprotein(a), or Lp(a), did not reduce the risk of heart attacks or strokes in a large clinical trial. The phase 3 Lp(a)Horizon trial involved 8,323 patients with elevated Lp(a) who had already experienced cardiovascular events or had established cardiovascular disease. While the drug, pelacarsen, successfully lowered Lp(a) levels, this reduction did not translate into a decreased risk of major cardiovascular events, according to Dr. Shreeram Aradhye, Novartis' chief medical officer.

This is significant for people concerned about heart health, especially since around 20% of the global population has elevated Lp(a) levels, which are linked to increased cardiovascular risk. The hope was that lowering Lp(a) could help prevent further heart-related issues in high-risk individuals. However, the trial's outcome suggests that simply lowering Lp(a) may not be enough to improve cardiovascular health in these patients.

The evidence from this trial indicates that while the drug reduced Lp(a) levels, its effectiveness in preventing cardiovascular events remains unproven. This was a large study, but it still leaves questions about the relationship between Lp(a) levels and heart health. Other drugs targeting Lp(a) are in development, and some may achieve greater reductions in Lp(a) levels, potentially leading to better outcomes. Experts believe that the field of Lp(a) research will continue to advance, despite this setback.

For now, if you have concerns about your cardiovascular health, it’s important to discuss your risk factors with your healthcare provider. They can help you understand your Lp(a) levels and what steps you might take to manage your heart health.